Respiratory Syncytial Virus-An Update for Prenatal and Primary Health Providers

Alisa B Kachikis; Hye Cho; Janet A Englund

doi:10.1016/j.ogc.2023.02.011

Respiratory Syncytial Virus-An Update for Prenatal and Primary Health Providers

Obstet Gynecol Clin North Am. 2023 Jun;50(2):421-437. doi: 10.1016/j.ogc.2023.02.011. Epub 2023 Apr 5.

Authors

Alisa B Kachikis¹, Hye Cho², Janet A Englund³

Affiliations

¹ Department of Obstetrics & Gynecology, University of Washington, 1959 Northeast Pacific Street, Box 356460, Seattle, WA 98195, USA. Electronic address: abk26@uw.edu.
² SUNY Upstate Medical University, Syracuse, NY, USA.
³ Department of Pediatrics, Seattle Children's Hospital Pediatric Infectious Diseases, Seattle Children's Hospital Research Institute, University of Washington, Seattle, WA, USA.

PMID: 37149320
DOI: 10.1016/j.ogc.2023.02.011

Abstract

Respiratory syncytial virus (RSV) infection is a significant cause of morbidity and mortality among infants aged younger than 1 year, adults aged 65 years or older, and immunocompromised persons. Limited data exist on RSV infection in pregnancy and further research is needed. Strides are being made to develop vaccines, including vaccines for maternal immunization, as well as monoclonal antibodies for disease prevention.

Keywords: Lower respiratory tract infection (LRTI); Pneumonia; RSV; Respiratory syncytial virus; Upper respiratory infection (URI).

Publication types

Review

MeSH terms

Adult
Female
Humans
Infant
Pregnancy
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus, Human*
Vaccination

Grants and funding

K23 AI153390/AI/NIAID NIH HHS/United States